Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be presenting research and meeting potential partners at ProBiota 2024 between 7-9 February 2024, in Milan.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned for scientists and industry leaders who are seeking to translate the latest science into new products in the supplements and ingredients market.

The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit.  These synbiotics represent an area of growing market interest as a means to bring innovation and differentiation into the probiotic market with a forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size & Share Analysis - Industry Research Report - Growth Trends (mordorintelligence.com)

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be presenting our research on synbiotics at ProBiota. Attending conferences like ProBiota, which attract scientists from around the world, allow us to present our work to industry and increases awareness of OptiBiotix and its products. This often attracts commercial interest in our technology and helps build the product pipeline in different territories and with different partners. This increases the scale of the opportunity, and the potential value of OptiBiotix." 

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI) brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be presenting research and meeting potential partners at ProBiota 2024 between 7-9 February 2024, in Milan.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned for scientists and industry leaders who are seeking to translate the latest science into new products in the supplements and ingredients market.

The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit.  These synbiotics represent an area of growing market interest as a means to bring innovation and differentiation into the probiotic market with a forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size & Share Analysis - Industry Research Report - Growth Trends (mordorintelligence.com)

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be presenting our research on synbiotics at ProBiota. Attending conferences like ProBiota, which attract scientists from around the world, allow us to present our work to industry and increases awareness of OptiBiotix and its products. This often attracts commercial interest in our technology and helps build the product pipeline in different territories and with different partners. This increases the scale of the opportunity, and the potential value of OptiBiotix." 

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI) brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be presenting research and meeting potential partners at ProBiota 2024 between 7-9 February 2024, in Milan.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned for scientists and industry leaders who are seeking to translate the latest science into new products in the supplements and ingredients market.

The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit.  These synbiotics represent an area of growing market interest as a means to bring innovation and differentiation into the probiotic market with a forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size & Share Analysis - Industry Research Report - Growth Trends (mordorintelligence.com)

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be presenting our research on synbiotics at ProBiota. Attending conferences like ProBiota, which attract scientists from around the world, allow us to present our work to industry and increases awareness of OptiBiotix and its products. This often attracts commercial interest in our technology and helps build the product pipeline in different territories and with different partners. This increases the scale of the opportunity, and the potential value of OptiBiotix." 

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI) brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be presenting research and meeting potential partners at ProBiota 2024 between 7-9 February 2024, in Milan.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned for scientists and industry leaders who are seeking to translate the latest science into new products in the supplements and ingredients market.

The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit.  These synbiotics represent an area of growing market interest as a means to bring innovation and differentiation into the probiotic market with a forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size & Share Analysis - Industry Research Report - Growth Trends (mordorintelligence.com)

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be presenting our research on synbiotics at ProBiota. Attending conferences like ProBiota, which attract scientists from around the world, allow us to present our work to industry and increases awareness of OptiBiotix and its products. This often attracts commercial interest in our technology and helps build the product pipeline in different territories and with different partners. This increases the scale of the opportunity, and the potential value of OptiBiotix." 

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI) brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be presenting research and meeting potential partners at ProBiota 2024 between 7-9 February 2024, in Milan.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned for scientists and industry leaders who are seeking to translate the latest science into new products in the supplements and ingredients market.

The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit.  These synbiotics represent an area of growing market interest as a means to bring innovation and differentiation into the probiotic market with a forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size & Share Analysis - Industry Research Report - Growth Trends (mordorintelligence.com)

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be presenting our research on synbiotics at ProBiota. Attending conferences like ProBiota, which attract scientists from around the world, allow us to present our work to industry and increases awareness of OptiBiotix and its products. This often attracts commercial interest in our technology and helps build the product pipeline in different territories and with different partners. This increases the scale of the opportunity, and the potential value of OptiBiotix." 

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI) brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be presenting research and meeting potential partners at ProBiota 2024 between 7-9 February 2024, in Milan.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned for scientists and industry leaders who are seeking to translate the latest science into new products in the supplements and ingredients market.

The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit.  These synbiotics represent an area of growing market interest as a means to bring innovation and differentiation into the probiotic market with a forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size & Share Analysis - Industry Research Report - Growth Trends (mordorintelligence.com)

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be presenting our research on synbiotics at ProBiota. Attending conferences like ProBiota, which attract scientists from around the world, allow us to present our work to industry and increases awareness of OptiBiotix and its products. This often attracts commercial interest in our technology and helps build the product pipeline in different territories and with different partners. This increases the scale of the opportunity, and the potential value of OptiBiotix." 

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI) brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.